Pfizer Inc. (PFE)
Pfizer loses bid to recoup $75 million left over from SEC settlement
A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange Commission settlement with billionaire Steven A. Cohen's hedge fund SAC Capital in an insider trading case.
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
On Monday, BridgeBio Pharma, Inc. BBIO presented initial outcomes from the ATTRibute-CM open-label extension (OLE) study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions.
2 High-Yield Dividend Stocks I Can't Stop Buying
2 High-Yield Dividend Stocks I Can't Stop Buying
Stock Of The Day: Is Pfizer Set Up To Rally?
Pfizer Inc. PFE shares are lower on Thursday due to news that President-elect Donald Trump picked Robert F. Kennedy Jr. as his next secretary of the Department of Health and Human Services.
Pfizer (PFE) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer Inc. (PFE) UBS Global Healthcare Conference (Transcript)
Pfizer Inc. (NYSE:PFE ) UBS Global Healthcare Conference November 13, 2024 3:30 PM ET Company Participants Aamir Malik - Chief Commercial Officer US Conference Call Participants Trung Huynh - UBS Trung Huynh Okay, great. I think we're at the half hour.
Down -11.04% in 4 Weeks, Here's Why You Should You Buy the Dip in Pfizer (PFE)
Pfizer (PFE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Should Value Investors Buy Pfizer (PFE) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Down -9.77% in 4 Weeks, Here's Why You Should You Buy the Dip in Pfizer (PFE)
Pfizer (PFE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Exclusive: Pfizer explores sale of hospital drugs unit, sources say
Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core assets, according to three people familiar with the matter.
Pfizer: The Tide Finally Turning
Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant. With business and stock excess seemingly totally wrung out, and with expectations now about as low as ever, long-term investors holding or buying from this starting point could be positioned well, as Pfizer has recently shown exciting signs of bouncing back into growth. Pfizer has increased its dividend for 14 consecutive years, with a 10-year dividend growth rate of 10.2%.
